Recent evidence from clinical and preclinical studies shows that combinations of an anti-PD-1/PD-L1 antibody with conventional cancer therapies, such as radiotherapy and chemotherapy, are more effective than either treatment alone [9–12]. Here, CD274 is linked to cancer.